Perrigo Co. has begun rolling out minoxidil 5% foam to its retail and wholesale customers.


Perrigo, generic Rogaine foam, minoxidil 5% foam, store brand, regrowth of hair, Stiefel Research Australia, generic marketing exclusivity


































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Perrigo launches generic Rogaine foam

March 1st, 2012

ALLEGAN, Mich. – Perrigo Co. has begun rolling out minoxidil 5% foam to its retail and wholesale customers.

The company said Thursday that the product, marketed under store brands or own-label brands, is comparable to Rogaine 5% Foam Hair Regrowth Treatment.

Perrigo had announced in May that it received final approval from the Food and Drug Administration for its abbreviated new drug application for the over-the-counter minoxidil foam.

Rogaine 5% Foam is a treatment for the regrowth of hair on the top of the scalp, and the product's estimated annual sales are about $60 million, according to Perrigo.

Just over a year ago, Perrigo announced that it successfully settled its Hatch-Waxman litigation relating to minoxidil 5% foam brought by Stiefel Research Australia Pty. Ltd., a GlaxoSmithKline company. Perrigo said that since it was the first party to challenge the brand patent, it's entitled to 180 days of generic marketing exclusivity.

Advertisement